market folly

John Paulson's hedge fund firm Paulson & Co has filed an amended 13G with the SEC regarding its stake in Enzymotec (ENZY).  Per the filing, Paulson now owns 9.17% of the company with over 2.10 million shares.

This is a decrease of around 2.1 million shares in their position size.  They previously owned 4.2 million shares at the end of the second quarter.  The new filing was made due to portfolio activity on August 23rd.

For more on this hedge fund, we've posted other recent activity from Paulson & Co here.

Per Google Finance, Enzymotec is "a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases."